Management of High-Risk Localized Prostate Cancer
Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/641689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168461208059904 |
|---|---|
| author | Ariel E. Marciscano Matthew E. Hardee Nicholas Sanfilippo |
| author_facet | Ariel E. Marciscano Matthew E. Hardee Nicholas Sanfilippo |
| author_sort | Ariel E. Marciscano |
| collection | DOAJ |
| description | Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that men with high-risk features who are treated in a multimodal fashion at the time of initial diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated benefits to this subset of patients. However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve optimal disease control. |
| format | Article |
| id | doaj-art-a789e3a9e9e94dea99bfd282fdd243a1 |
| institution | OA Journals |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-a789e3a9e9e94dea99bfd282fdd243a12025-08-20T02:20:57ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/641689641689Management of High-Risk Localized Prostate CancerAriel E. Marciscano0Matthew E. Hardee1Nicholas Sanfilippo2Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USADepartment of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USADepartment of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USATraditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that men with high-risk features who are treated in a multimodal fashion at the time of initial diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated benefits to this subset of patients. However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve optimal disease control.http://dx.doi.org/10.1155/2012/641689 |
| spellingShingle | Ariel E. Marciscano Matthew E. Hardee Nicholas Sanfilippo Management of High-Risk Localized Prostate Cancer Advances in Urology |
| title | Management of High-Risk Localized Prostate Cancer |
| title_full | Management of High-Risk Localized Prostate Cancer |
| title_fullStr | Management of High-Risk Localized Prostate Cancer |
| title_full_unstemmed | Management of High-Risk Localized Prostate Cancer |
| title_short | Management of High-Risk Localized Prostate Cancer |
| title_sort | management of high risk localized prostate cancer |
| url | http://dx.doi.org/10.1155/2012/641689 |
| work_keys_str_mv | AT arielemarciscano managementofhighrisklocalizedprostatecancer AT matthewehardee managementofhighrisklocalizedprostatecancer AT nicholassanfilippo managementofhighrisklocalizedprostatecancer |